German biotech firm BioNTech announced today (May 10) that it will establish a regional headquarters in Singapore.
The new Singapore headquarters will also have a fully integrated mRNA manufacturing facility and will have the support of the Singapore Economic Development Board (EDB).
This move is part of the country’s strategy to grow the biopharmaceutical industry here, and EBD chairman Beh Swan Gin said the investment will allow Singapore to “develop capabilities in a major new therapeutic modality”.
BioNTech co-founder and CEO Ugur Sahin also noted that Singapore has an “excellent business climate” and the opening of the regional headquarters is a strategic step for the company in expanding its headquarters. global footprint “.
BioNTech’s Singapore office is scheduled to open in 2021, which is also expected to begin construction of its manufacturing plant.
According to the company, the facility could be operational as early as 2023 and create up to 80 jobs in Singapore. However, no information was released on the amount the company invested in Singapore.
BioNTech said in a Press release that the new mRNA manufacturing facility “will leverage state-of-the-art digital manufacturing and infrastructure” and will be “equipped to produce a range of new messaging RNA (mRNA) and therapeutic vaccines for infectious diseases and cancer “.
The company had partnered with Pfizer to develop a Covid-19 vaccine using mRNA technology.
The Health Sciences Authority (HSA) has assessed that the Pfizer-BioNTech and Modern COVID-19 vaccines, the two vaccines currently available in Singapore, meet safety and efficacy standards.
Last month, the Ministry of Health announced that children under 45 will be able to reserve their vaccination strips soon. This means that vaccination against Covid-19 will be available to all Singaporeans over the age of 16.
Featured Image Credit: World Pharma Today